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Abstract
Background: Hypoadiponectinemia predicts the development of diabetes and hypertension, both being potent
atherosclerotic risk factors. Whether adiponectin predicts the progression of early atherosclerosis remains
unclear. In this 5-year prospective study, we examined the relationship between serum adiponectin and carotid
intima media thickness (CIMT), a marker of subclinical atherosclerosis.
Methods: A total of 265 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence
Study, with no known cardiovascular disease, underwent CIMT measurement at baseline and at 5 years.
Results: In all, 129 men and 136 women, aged 54.6– 12.3 years, were studied. Median CIMT at baseline was
0.63 mm (interquartile range 0.52–0.73 mm) and increased to 0.67 mm (0.56–0.78 mm) after 5 years (P< 0.001).
CIMT increment correlated with baseline adiponectin, age, and smoking (all P< 0.05) and baseline CIMT
(P< 0.001), but not with sex, fasting glucose, lipid profiles, hypertension, or diabetes. In multiple linear regression
analysis, baseline serum adiponectin level was an independent predictor of CIMT increment b (standardized
beta)= - 0.17, P= 0.015], after adjusting for age, smoking, baseline CIMT, hypertension, body mass index,
fasting glucose, low-density lipoprotein cholesterol, and triglycerides.
Conclusion: Hypoadiponectinemia predicted CIMT progression, independent of known predictive factors such
as age, smoking, hyperlipidemia, and hypertension.
Introduction
Adiponectin, the most abundant adipokine secretedfrom adipose tissues, exhibits insulin-sensitizing, anti-
inflammatory, and antiatherogenic properties in animal
models.1,2 In humans, we and others have shown that hypo-
adiponectinemia predicts the development of cardiovascular
risk factors, including hypertension2,3 and type 2 diabetes
mellitus,4 in prospective studies. Carotid intima media thick-
ness (CIMT), a marker of subclinical atherosclerosis, is in-
creased in subjects with cardiovascular risk factors and is an
independent predictor of stroke and myocardial infarction.5 In
cross-sectional studies, serum adiponectin levels have been
shown to correlate inversely with CIMT in young obese ado-
lescents,6 healthy middle-aged adults,7 and subjects with or
without the metabolic syndrome.8 Although data from these
studies would suggest an etiologic role for hypoadiponecti-
nemia in atherosclerosis, there has been limited data on the
prospective relationship between circulating adiponectin lev-
els and CIMT in subjects without known cardiovascular dis-
ease (CVD). It remains an open question whether adiponectin
plays a causal role in the development of atherosclerosis.
Therefore, in this 5-year prospective study, we investigated the
relationship between serum adiponectin levels and CIMT in a
community-based cohort of subjects with no known CVD.
Methods
Subjects
Subjects were recruited from the community-based
Hong Kong Cardiovascular Risk Factor Prevalence Study
(CRISPS).2,9 Briefly, 2875 unrelated subjects, aged 25–74
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years, were randomly recruited to participate in a population-
based study to assess the prevalence of cardiovascular risk
factors in our Chinese population between 1995 and 1996.
All subjects who returned for CRISPS2 follow-up (n = 1944)
were invited to undergo CIMT measurements at CRISPS2
and prospectively at CRISPS3. Subjects with known history
of CVD were excluded from the present study. A total of
265 subjects with no known CVD consented to participate in
the present study. These subjects had baseline and follow-up
CIMT measurements at the second (CRISPS2) and third
(CRISPS3) assessments. CRISPS2 was conducted in 2000–
2004 and CRISPS3 in 2005–2008. CIMT measurements
were performed by the same radiologist (S.C.W.C.) at the
Department of Radiology, Queen Mary Hospital. Complete
baseline demographic and biochemical data were available
for all subjects. Detailed medical, drug, and family histories,
including history of CVD, were obtained using a detailed
questionnaire. Hypertension was defined as sitting blood
pressure ‡ 140/90 mmHg or on regular antihypertensive drugs.
Subjects were classified as having diabetes mellitus according
to the World Health Organization 1998 diagnostic criteria.10
Anthropometric and biochemical measurements
All subjects were assessed after an overnight fast. The
details of anthropometric measurements [including height,
weight, body mass index (BMI), waist circumference (WC),
systolic (SBP) and diastolic blood pressure (DBP)], and mea-
surements of biochemical variables (fasting plasma insulin,
glucose, and lipid profile) were reported previously.2,9,11 The
homeostasis model assessment of insulin resistance (HOMA-
IR) was calculated using the following formula: Fasting plas-
ma glucose (mmol/L)· fasting insulin (microunits/mL)/22.5.
Serum adiponectin levels, measured at baseline (CRISPS2),
were determined with an enzyme-linked immunosorbent assay
(ELISA) established in our laboratory.11,12
Measurement of CIMT and definition
of carotid plaques
Intima media thickness of the common carotids was as-
sessed on B-mode ultrasound (ATL HDI 3000 and 5000 ul-
trasound system; Advanced Technology Laboratories, Bothell,
WA) using high-resolution 10- to 12-MHz linear transducers,
as previously described.9 Longitudinal views of both common
carotid arteries were obtained through an anterolateral ap-
proach. The best image was selected to show the far wall
intimal–lumen interface as a continuous straight line. Three
determinations of CIMT were made at 2 cm proximal to the
bulb and at the site of greatest thickness. The values at each site
were averaged, and the highest value of the averaged CIMT
used as the representative value for each individual.
Statistical analysis
All statistical analyses were performed using SPSS Sta-
tistics 19 (SPSS, Chicago, IL). Change in CIMT (DCIMT)
was defined as the difference between baseline and year-5
measures. Data that were not normally distributed, as de-
termined using the Kolmogorov–Smirnov test, were natural
logarithmically transformed to obtain near normality before
analysis. Values are reported as means – standard deviation
(SD) or medians with interquartile range (IQR). One-way
analysis of variance (ANOVA) for continuous variables or
chi-squared test for categorical variables was used as ap-
propriate for comparisons between groups. The relationship
between the CIMT progression with adiponectin level and
other metabolic variables at baseline were assessed by
Pearson correlation analysis.
Multiple linear regression models were performed to assess
the association between adiponectin level at baseline and
dCIMT as a dependent variable. We performed regression
modeling on those baseline parameters with significant cor-
relations with the CIMT progression on univariate analyses.
We then repeated the regression model with full adjustment
for traditional CVD risk factors, including age, smoking sta-
tus, BMI or WC, fasting glucose, hypertension, low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein cho-
lesterol (HDL-C), or triglycerides (TGs), and CIMT at baseline.
In all statistical tests, two-sided P values<0.05 were consid-
ered significant.
Ethics statement
The study was approved by the ethics committee of the
Faculty of Medicine, University of Hong Kong. All subjects
gave written informed consent.
Results
A total of 265 subjects (129 men and 136 women) for
whom baseline and follow-up CIMT measurements were
available at the second (CRISPS2) and third (CRISPS3) as-
sessments, were included in this study. The baseline clinical
characteristics of the subjects are summarized in Table 1. Of
these subjects, 76 (28.7%) were current or former smokers.
The median adiponectin level at baseline was 5.29mgrams/
mL (interquartile range 3.6–7.69mg/mL). Serum adiponectin
levels were lower in men (4.01mg/mL; 2.98–6.06mg/mL)
than in women (6.67mg/mL; 4.18–9.43mg/mL) (P< 0.001).
Adiponectin was negatively correlated with baseline CIMT
(age-adjusted r= - 0.184, P= 0.003). Adiponectin was also
negatively correlated with BMI, WC, blood pressure, fasting
glucose, HOMA-IR, and TGs, and positively correlated with
HDL-C (all P< 0.05; data not shown). CIMT at baseline was
0.63 mm (0.52–0.73 mm) and increased significantly to
0.67 mm (0.56–0.78 mm) over 5 years (P< 0.001). Men had
significantly thicker CIMT at baseline and at follow-up,
compared to women (P< 0.001). Both men and women had
significant increments in CIMT at year 5 compared to base-
line (P< 0.001). DCIMT values were not significantly dif-
ferent between the sexes (P= 0.122).
Low adiponectin levels at baseline predicted a greater IMT
increment (r= - 0.13, P= 0.036). DCIMT also correlated in-
versely with age and baseline CIMT (r= - 0.12, P= 0.048,
and r= - 0.32, P< 0.001, respectively), but showed no sig-
nificant correlation with BMI, WC, SBP, DBP, fasting glu-
cose, insulin resistance as measured by HOMA-IR, serum
creatinine, or lipid levels (Table 2). Subjects who were cur-
rent or former smokers had a significantly greater increase in
CIMT over 5 years than nonsmokers [0.07 (0.00–0.15) vs.
0.03(0.02- 0.10), respectively; P= 0.029). The presence of
diabetes or hypertension was not associated with DCIMT.
In multiple linear regression analysis, baseline adipo-
nectin levels (standardized b = - 0.14, P = 0.023) was a
significant independent predictor of DCIMT, after adjusting
for parameters with significant correlations with DCIMT in
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univariate analyses (model 2, Table 3). Baseline adiponectin
levels remained a significant predictor of DCIMT (b= - 0.17,
P= 0.015), even after adjusted for other traditional CVD risk
factors, including BMI (or WC), fasting glucose, hyperten-
sion, LDL, and TGs (model 3, Table 3). With separate re-
gression analysis on the basis of gender, the independent
association of baseline adiponectin with DCIMT was signif-
icant in men (b= - 0.23, P= 0.026), but not in women
(P= 0.290) (Table 3).
Discussion
In this 5-year prospective study of a population-based
cohort with no known CVD at baseline, serum adiponectin
level was shown to predict the progression in carotid ath-
erosclerosis, as reflected by the increment in CIMT, inde-
pendent of conventional cardiovascular risk factors.
Previous cross-sectional studies demonstrated an inverse
association between serum adiponectin and CIMT in Cauca-
sian7,8,13 and multiethnic populations.14,15 However, it has been
questioned whether the association of serum adiponectin with
CIMT occurred secondary to the relationship of circulating
adiponectin status with other cardiovascular risk factors. In
populations without clinically manifest CVD, an association of
adiponectin with CIMT was observed in cross-sectional stud-
ies, independent of other cardiovascular risks such as diabe-
tes.7,8,14 However, in subjects with a history of CVD, the
relationship between CIMT and adiponectin was attenuated
after full adjustment for risk factors including WC, DBP, HDL-
C, and glycated haemoglobin (HbA1c).16 This suggests that
Table 1. Clinical and Biochemical Characteristics of Study Subjects
All subjects Men Women
P value
(men vs. women)
N 265 129 136 —
Age (years) 54.6– 12.3 54.3 – 12.3 54.9 – 12.3 0.688
BMI (kg/m2) 24.9– 3.73 25.1 – 3.50 24.7 – 3.94 0.443
Waist circumference (cm) 80.9– 10.2 85.7 – 9.21 76.4 – 9.06 <0.001
Current/former smoker (%) 28.7 54.3 4.40 <0.001
Fasting glucose (mmol/L) 5.33– 1.17 5.52 – 1.47 5.15 – 0.76 0.009
HOMA-IR 1.78 (1.29–2.71) 1.87 (1.32–2.94) 1.73 (1.27–2.58) 0.207
Diabetes (%) 12.5 15.6 9.6 0.136
Systolic blood pressure (mmHg) 125 – 19.4 127 – 19.2 123– 19.3 0.053
Diastolic blood pressure (mmHg) 75– 10.8 94– 12.5 89.8 – 11.0 <0.001
Mean arterial pressure (mmHg) 92– 12.0 94– 12.5 90 – 11.0 0.001
Antihypertensive treatment (%) 18.1 20.9 15.4 0.234
Hypertension (%) 32.8 37.2 28.7 0.018
Total cholesterol (mmol/L) 5.37– 0.92 5.39 – 0.88 5.34 – 0.95 0.652
HDL-C (mmol/L) 1.31– 0.36 1.16 – 0.29 1.46 – 0.35 <0.001
LDL-C (mmol/L) 3.40– 0.81 3.50 – 0.82 3.31 – 0.80 0.048
Triglycerides (mmol/L) 1.20 (0.80–1.90) 1.30 (0.90–2.10) 1.10 (0.70–1.50) <0.001
Lipid-lowering treatment (%) 3.77 2.38 5.43 0.336
Serum creatinine (mmol/L) 72.0 (62.0–86.0) 86.0 (77.0–96.0) 62.0 (55.0–68.0) <0.001
eGFR 83.9 (73.6–98.0) 80.2 (70.2–92.9) 85.9 (76.0–102.2) 0.002
Adiponectin (mg/mL) 5.29 (3.60–7.96) 4.01 (2.98–6.06) 6.67 (4.18–9.43) <0.001
CIMT at baseline (mm) 0.63 (0.52–0.73) 0.62 (0.54–0.74) 0.58 (0.50–0.70) 0.019
CIMT at year 5 follow-up (mm) 0.67 (0.56–0.78) 0.71 (0.60–0.82) 0.63 (0.53–0.75) <0.001
Change in CIMT (mm) 0.05 (–0.02 to 0.13) 0.05 (–0.02 to 0.13) 0.03 (–0.02 to 0.01) 0.122
Data are expressed as mean – standard deviation (SD) or median (interquartile range).
Bold indicates significant P-values < 0.05.
BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance; HDL-C, high-density lipoprotein cholesterol;
LDL, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; CIMT, carotid intima media thickness.
Table 2. Pearson Correlation Between Change
in Carotid Intima Media Thickness and Other
Baseline Parameters
Baseline variables r P value
Age - 0.12 0.048
Adiponectina - 0.13 0.036
Baseline CIMTa - 0.32 <0.001
BMI 0.06 0.323
WC 0.06 0.375
SBP - 0.08 0.212
DBP - 0.04 0.550
Mean arterial pressure - 0.07 0.307
Fasting glucose - 0.05 0.447
HOMA-IRa 0.01 0.851
Cholesterol 0.02 0.700
HDL-C 0.04 0.577
LDL-C 0.05 0.400
Triglyceridesa - 0.05 0.388
Creatininea - 0.01 0.938
Estimated glomerular filtration ratea 0.11 0.087
aLog-transformed before analysis; change in carotid intima media
was log-transformed before analysis.
Bold indicates significant P-values < 0.05.
CIMT, carotid intima media thickness; BMI, body mass index;
WC, waist circumference; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HOMA-IR, homeostasis model assessment
of insulin resistance; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol.
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other risk factors related to insulin resistance and the metabolic
syndrome may contribute to the inverse relationship between
adiponectin and CIMT, depending on the selected population.16
In prospective studies, the relationship between adipo-
nectin and CIMT was also not straightforward. In the Car-
diovascular Risk in Young Finns Study, adiponectin levels at
baseline were associated with baseline and 6-year CIMT in
univariate analysis.17 In a study of 85 Japanese hemodialysis
patients with high cardiovascular risk and elevated serum
adiponectin levels, no significant correlation was found be-
tween DCIMT and baseline adiponectin levels or the change
in total or high-molecular-weight (HMW) adiponectin, but
the change in the ratio of HMW to total adiponectin
(DHMWR) was independently associated with CIMT pro-
gression at 1 year.18 In 142 postmenopausal nondiabetic
women studied by Stork et al. in Germany,19 a significant
linear relationship was not observed between age-adjusted
DCIMT and baseline adiponectin levels. Whereas mean
DCIMT was almost identical in the top three quartiles of
baseline adiponectin levels, subjects in the lowest quartile
showed a significantly higher DCIMT compared to the rest of
the subjects, even after adjustment for confounding factors.19
This threshold effect was not seen in other cross-sectional
studies. In the current study, we observed instead a continu-
ous inverse relationship between baseline serum adiponectin
and DCIMT that persisted on multivariate analysis. This
discrepancy may be attributed to differences in study subject
characteristics and study design. It should be noted that the
study by Stork et al. included high-risk postmenopausal wo-
men with baseline CIMT > 1 mm, recruited from a random-
ized control trial to study the effects of hormone replacement
therapy that could impact on serum adiponectin level.20
Our current study, on the other hand, involved more
subjects with a wider age range, included both sexes from a
population-based study, and there was no known CVD at
baseline. Whereas DCIMT was 0.023 mm after 1 year in the
study by Stork et al., DCIMT in the current study was
0.05 mm after the much longer follow-up of 5 years. This,
together with the median baseline CIMT of 0.63 mm (range
0.52–0.73 mm), would support our cohort being of much
lower atherosclerotic risk compared to that of Stork et al.19
Adiponectin acts on both the liver and peripheral tissues to
enhance insulin sensitivity. Indeed, baseline serum adipo-
nectin levels correlated inversely with baseline HOMA-IR
(r= - 0.46, P< 0.001) in the current study. However, al-
though insulin resistance is a known risk factor of athero-
sclerotic diseases,21 we did not find a significant correlation
between HOMA-IR and CIMT progression in our study. It
should be noted that HOMA-IR, as a surrogate index of in-
sulin resistance, primarily reflects on hepatic insulin resis-
tance and correlates less well with CIMT in cross-sectional
studies, when compared to insulin resistance indexes that
reflect on peripheral or muscle insulin sensitivity.22 Further-
more, the relatively low baseline atherosclerosis risk of our
cohort may have also contributed to the lack of a correlation
between HOMA-IR and CIMT progression, because this
community-based cohort was relatively nonobese and the
vast majority of the subjects were not diabetic. Their base-
line TGs and HDL-C levels also did not suggest a high level
of insulin resistance. It would appear that, in this cohort, the
effect of adiponectin on CIMT progression was mainly
mediated through its antiatherogenic, anti-inflammatory,
and antioxidative actions,1 rather than its insulin-sensitizing
effect.
The findings of the current study provide support for adi-
ponectin as a potentially modifiable risk factor for athero-
sclerosis before the clinical manifestation of CVD, even in a
relatively low-risk population. In the Framingham Offspring
Study, a higher adiponectin level predicted lower future
coronary heart disease (CHD) events in men initially free of
CHD.23 Amongst Asians, in a Korean population without
CVD, a low adiponectin level was again a significant risk
factor for the development of cardiovascular events.24 On the
other hand, a compensatory increase in adiponectin in re-
sponse to the presence of CVD25 probably contributes to the
association between elevated CVD risk and high adiponectin
levels observed in subjects with known CVD. Indeed, in this
and our earlier studies, serum adiponectin levels in men were
significantly lower than those in women.12 Sexual dimor-
phism in serum adiponectin concentrations may explain the
gender-specific effect of adiponectin on carotid atheroscle-
rosis, as we have previously demonstrated that the lower
adiponectin levels in men were due to the suppressive effects
of testosterone on adiponectin secretion.12
A genetic variant in the ADIPOQ gene, adipo4 (rs266729),
was found to be nominally associated with CIMT and low
circulating adiponectin levels in obese subjects from the
Carotid Atherosclerosis Progression Study,13 providing add-
itional support for a causal role of hypoadiponectinemia in
early atherosclerosis. In that study, the association with hypo-
adiponectinemia persisted after adjusting for HbA1c, sug-
gesting a direct effect of hypoadiponectinemia to increase
CVD risk, rather than through inducing glucose intolerance.13
Our data also suggest that CIMT is more closely related to
adiponectin levels than blood glucose, lipid profile, or blood
pressure.
Table 3. Linear Regression Analysis Showing the Independent Association of Serum Adiponectin
with Change in Carotid Intima Media Thickness
Model 1 Model 2 Model 3
N Standardized beta (P value) Standardized beta (P value) Standardized beta (P value)
All 265 - 0.13 (0.032) - 0.14 (0.023) - 0.17 (0.015)
Men 129 - 0.20 (0.026) - 0.18 (0.042) - 0.23 (0.026)
Women 136 - 0.03 (0.749) - 0.08 (0.334) - 0.09 (0.290)
Model 1, unadjusted; model 2, age, ever smoke, adiponectin, and CIMT at baseline; model 3, model 2 + additionally adjusted with HT,
BMI, or WC, fasting glucose, LDL-C, and TGs or HDL-C.
Bold indicates significant P-values < 0.05.
CIMT, carotid intima media thickness; HT, hypertension; BMI, body mass index; WC, waist circumference; LDL-C, low-density
lipoprotein cholesterol; TGs, triglycerides; HDL-C, high-density lipoprotein cholesterol.
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This study has several limitations. The findings from this
Chinese cohort may not be directly extrapolated to other
ethnic populations. However, recent data have shown that
the relationship between adiponectin and CIMT did not
differ significantly across racial/ethnic groups, even after
controlling for vascular risk factors.15 We have adjusted for
the relevant confounding factors. However, other con-
founding factors, such as the effect of attrition, may lead to
potential bias. There may also be selection bias because
subjects who participated in the study may be more health
conscious and more willing to consent, and therefore, not
representative of the entire CRISPS cohort. Nonetheless, the
relationships between adiponectin and other cardiometa-
bolic risk factors were similar to findings in previous stud-
ies.2,4 Therefore, we believe that this cohort with relatively
low cardiovascular risk would be representative of other
population-based cohorts. Moreover, the HMW form of
adiponectin was not measured; hence, the effect of adipo-
nectin oligomerization on subclinical atherosclerosis cannot
be assessed. However, total adiponectin levels, as measured
in this study, correlate strongly with the HMW form.26
Although we have not accounted for intraobserver vari-
ability in the measurement of CIMT, standardized protocols
as previously described9 have been used at baseline and
year-5 CIMT measurements.
In conclusion, this 5-year prospective study demonstrated
that hypoadiponectinaemia was an independent risk factor
for the progression of CIMT, a marker of early atheroscle-
rosis, even after adjusting for other cardiovascular risk
factors, in men without known CVD. This is in keeping with
a vasoprotective effect of adiponectin in humans, as has
been demonstrated in animal studies.
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